Instructions on contraindications and caution for sparsentan/sparsentan

When using sparsentan/sparsentan (Sparsentan) to treat primary immunoglobulin A nephropathy (IgAN) and other diseases, its contraindications and precautions are crucial to ensure patient safety and efficacy. First of all, pregnant women are clearly listed as an absolute contraindication for Sparsentan. Drugs may have serious adverse effects on fetal development, especially the kidneys and cardiovascular system. Women who are pregnant and preparing for pregnancy should avoid using them to avoid serious consequences such as miscarriage and fetal malformations.

In addition, sparsentan is strictly prohibited from being taken simultaneously with similar angiotensin receptor blockers (ARB), endothelin receptor antagonists (ERA) or aliskiren. Combined use of drugs may lead to serious side effects such as hypotension, deterioration of renal function, and electrolyte imbalance, which greatly increases the patient's health risks. Please inform your doctor in detail about all medications you are taking before use to avoid potential drug interactions.

Patients with hepatic insufficiency need to be extremely cautious when using sparsentane. Liver enzymes, bilirubin and other indicators need to be monitored regularly to detect and deal with hepatotoxic reactions in a timely manner. Patients with hypotension, severe renal impairment, and electrolyte abnormalities are also those who should use it with caution. They must closely observe changes in their condition during treatment and adjust their medication regimen in a timely manner.

In addition, patients should avoid alcoholism, drug abuse and other behaviors that may increase the burden on the liver and kidneys while taking the medication, and maintain good living habits, which will help improve the efficacy and reduce the risk of side effects.

In summary, the safe use of sparsentane must strictly follow the principles of contraindications and caution. Doctors should develop individualized treatment plans based on the patient's specific conditions to ensure the safety and effectiveness of treatment. Patients need to actively cooperate and undergo regular inspections to ensure that the medication process is scientific and reasonable.

Reference materials:https://www.sparsentan.com/